Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Department of Pathology and Laboratory Medicine, |
RCV000500268 | SCV000591045 | pathogenic | not provided | no assertion criteria provided | clinical testing | The c.646-1G>C variant has not been reported in the literature nor previously identified by our laboratory. This variant is predicted to cause abnormal splicing because the nucleotide substitution occurs in the invariant region of the splice consensus sequence. In addition, in-silico or computational prediction software (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predicts a difference in splicing in 5 of 5 different programs, increasing the likelihood this variant is pathogenic. A different nucleotide change at the same position (c.646-1G>A) has been previously observed in one study in an individual with clinical features of FAP and they demonstrated that this variant abrogates the canonic splice-acceptor site of exon 6, leading to the activation of a cryptic “AG” splice-acceptor site by analyses of the cDNA and increasing the likelihood that the c.646-1G>C variant also has a functional consequence (Aceto 2005). Furthermore, this variant is of the type which is expected to cause the disorder. In summary, based on the above information, this variant is classified as Pathogenic. |